Asian Stocks Surge as Middle East Peace Hopes Lift Markets; SpaceX IPO Shatters Records 
Hanmi Semicon Shares Surge After $33 Million SpaceX Investment 
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids 
Oil Prices Fall as Trump Signals Iran Deal, Reducing Supply Risk Concerns 
New Zealand Unemployment and Inflation Debate Intensifies Ahead of 2026 Election 
US Stock Futures Rally as U.S.-Iran Peace Talks Boost Market Sentiment Despite Ongoing Strikes 
Asian Stocks Slide as Tech Selloff Deepens and US-Iran Conflict Escalates 
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion 
OpenAI Files Confidential IPO Draft as AI Giants Race Toward Public Markets 
Adobe Beats Q2 2026 Estimates, Raises Full-Year Outlook as AI Revenue Surges Despite Stock Drop 
Gold Prices Slide Toward Second Weekly Loss as Fed Rate Hike Expectations Weigh on Market 
Wall Street Slides as U.S.-Iran Tensions Escalate; Tech Stocks Extend Losses in 2026 
US Stock Futures Rise on Iran Peace Deal Hopes as SpaceX Debuts After Record IPO 
China Inflation Misses Forecast as Consumer Spending Stays Weak, Producer Prices Surge 
Trump Signals Opposition to USMCA Renewal as U.S. Reviews Trade Relations with Canada and Mexico 
Asian Stocks Slide, Oil Prices Climb as Middle East Tensions and Inflation Fears Shake Markets in 2026 
Japan Producer Prices Surge in May, Strengthening Expectations of BOJ Rate Hike 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
